Radiation Dermatitis & Skin Care Management

The federal sources are consistent and set a low threshold for reporting. NCI says: "Let your health care team know if you notice any skin changes so they can be treated promptly." MedlinePlus says: "Tell your provider if you have skin changes and any break or openings in your skin." ACS says: "Tell your cancer care team about any skin changes. They can help you manage pain and irritation and prevent infection."

MedlinePlus's discharge instructions for pelvic radiation are more specific about what warrants a call. "Contact your provider if you have pain that doesn't go away, a fever, severe vomiting or diarrhea, or blistering of the skin."

Notice what none of these sources do: none of them separate skin changes into routine versus same-day. That line is set locally. Ask your radiation team, before your skin starts reacting, which changes they want to see at your next daily treatment and which ones justify a phone call in between.

The word "burn" is misleading. Nothing is hot, and nothing scalds you. Radiation damages skin cells in the treated area faster than your body can replace them, and the visible result builds up over weeks. Clinicians call it radiation dermatitis. This page is about what actually happens to the skin, in what order, and which changes your team wants to hear about.

MedlinePlus puts the start at "two weeks or so after radiation treatment starts." Around then you may notice red or sunburned-looking skin, darkening, itching, bumps or rash, peeling, hair loss in the treated area, skin that feels thinner or thicker, soreness, swelling, sensitivity, numbness, or open sores.

Changes tend to build while treatment continues, because the daily doses keep arriving faster than repair. They do not stop the day treatment stops. The American Cancer Society says these problems "usually go away slowly after treatment ends." NCI's broader statement about radiation is that healthy cells damaged during treatment usually recover within a few months after treatment is over.

Some changes stay. ACS notes that "sometimes, the treated skin remains darker or more sensitive than it was before." MedlinePlus adds that your skin may remain darker, drier, and more sensitive to the sun. When hair grows back in the treated area, it may look different than before, and some areas of hair loss can be permanent.

If a nurse writes "grade 2 dermatitis" in your chart, that comes from the Common Terminology Criteria for Adverse Events, the NCI scale used to describe how severe a side effect is. The wording is worth knowing, because it explains why two people with red skin can be handled very differently.

• Grade 1. Faint erythema or dry desquamation. In plain terms, mild pinkness, or dry flaking and peeling.
• Grade 2. Moderate to brisk erythema, and patchy moist desquamation, mostly confined to skin folds and creases, with moderate swelling. In plain terms, deeper redness, some weeping in the folds, some swelling.
• Grade 3. Moist desquamation in areas other than skin folds and creases, with bleeding induced by minor trauma or abrasion. In plain terms, the weeping has spread beyond the creases, and the skin bleeds when rubbed.
• Grade 4. Life-threatening consequences, skin necrosis or ulceration of the full thickness of the dermis, spontaneous bleeding from the involved site, and a skin graft indicated.

The scale describes severity, not how likely each grade is. These sources do not state how often each grade occurs. Your own likelihood depends on the site treated, the dose, and your skin, so that is a question for your radiation team rather than something to read off a chart.

This is the change people are least prepared for. NCI describes a "moist reaction," in which the skin develops sores that "become painful, wet, and infected." It happens most often "in areas where the skin folds, such as around your ears, breast, or bottom": under the breast, in the armpit, in the groin, between the buttocks, behind the ear.

The distinction between dry and moist matters. Dry desquamation is flaking, like a peeling sunburn. Moist desquamation means the top layer is gone and the raw surface underneath is weeping. NCI's description flags infection as part of the picture. That is why this is the change that most often triggers a change in dressings, in supportive care, or occasionally a pause in treatment.

Skin that was treated months or years ago can flare again. NCI describes radiation recall: areas of previous radiation "become red, blister, peel, or hurt" when certain chemotherapy drugs are given. If old treated skin lights up after a new infusion, that is a recognized reaction, not a new burn, and it is worth reporting.

• Call your care team the same day if treated skin has opened or is weeping and you also feel feverish or unwell. MedlinePlus tells patients to make contact for a fever, and NCI notes that a moist reaction can become infected.
• Call your care team the same day if pain in the treated area will not settle, or severe vomiting or diarrhea arrives alongside the skin changes. MedlinePlus lists all of these in its radiation discharge instructions.
• Call your care team within a day or two if the area blisters, splits, or bleeds when lightly rubbed. That is the point where dressings or a change in plan are usually needed rather than more cream.

• National Cancer Institute, Skin and Nail Changes and Cancer Treatment: https://www.cancer.gov/about-cancer/treatment/side-effects/skin-nail-changes.
• MedlinePlus (U.S. National Library of Medicine), Pelvic radiation - discharge: https://medlineplus.gov/ency/patientinstructions/000059.htm.
• MedlinePlus (U.S. National Library of Medicine), Radiation therapy - skin care: https://medlineplus.gov/ency/patientinstructions/000735.htm.
• American Cancer Society, Radiation Therapy Effects on Different Parts of the Body: https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/effects-on-different-parts-of-body.html.
• NCI Common Terminology Criteria for Adverse Events, radiation dermatitis grading, as reproduced at NIH PubMed Central: https://pmc.ncbi.nlm.nih.gov/articles/PMC4447868/table/TB00891-4/.